BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023
MISSISSAUGA, Ontario, March 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2023. Key highlights include:
安大略省密西沙加，2024年3月13日（GLOBE NEWSWIRE）——BioSyent Inc.（“BioSyent”，多倫多證券交易所風險投資代碼：RX）今天公佈了截至2023年12月31日的第四季度（第四季度）和全年（財年）的財務業績。主要亮點包括：
| (CAD) | Q4 2023 |
% Change vs. Q4 2022 |
FY 2023 |
% Change vs. FY 2022 |
||
| Canadian Pharma Sales | 7,989,098 | 10% | 29,554,899 | 13% | ||
| International Pharma Sales | 54,750 | -54% | 1,047,747 | 53% | ||
| Total Company Sales | 8,273,686 | 11% | 31,590,302 | 13% | ||
| EBITDA1 | 1,650,301 | 5% | 7,926,478 | 7% | ||
| Net Income After Taxes (NIAT) | 1,450,791 | 21% | 6,460,127 | 18% | ||
| Fully Diluted EPS | 0.12 | 33% | 0.53 | 20% | ||
| （CAD） | 2023 年第四季度 |
% 變化 vs. 2022 年第四季度 |
2023 財年 |
% 變化 vs. 2022 財年 |
||
| 加拿大藥品銷售 | 7,989,098 | 10% | 29,554,899 | 13% | ||
| 國際藥品銷售 | 54,750 | -54% | 1,047,747 | 53% | ||
| 公司總銷售額 | 8,273,686 | 11% | 31,590,302 | 13% | ||
| EBITDA1 | 1,650,301 | 5% | 7,926,478 | 7% | ||
| 稅後淨收入 (NIAT) | 1,450,791 | 21% | 6,460,127 | 18% | ||
| 完全稀釋後的每股收益 | 0.12 | 33% | 0.53 | 20% | ||
- Return on Equity for FY 2023 was 19% as compared to 17% for FY 2022
- During FY 2023, repurchased for cancellation a total of 400,100 common shares under a Normal Course Issuer Bid (NCIB)
- Paid quarterly dividends of $0.04 per common share on March 15, 2023, June 15, 2023, September 15, 2023, December 15, 2023 and declared subsequent quarterly dividend of $0.045 per common share to be paid on March 15, 2024
- 2023財年的股本回報率爲19％，而2022財年的股本回報率爲17％
- 在2023財年，根據普通股發行人出價（NCIB）共回購了400,100股普通股以供註銷
- 於 2023 年 3 月 15 日、2023 年 6 月 15 日、2023 年 9 月 15 日、2023 年 12 月 15 日支付了每股普通股0.04美元的季度股息，並宣佈隨後的每股普通股0.045美元的季度股息將於2024年3月15日支付
"We reported our highest ever Canadian pharmaceutical sales in Q4 2023 with 10% growth over the prior period, driven by our established products," commented Mr. René Goehrum, President and CEO of BioSyent. During Q4 2023, we also commenced distribution of the new Gelclair oncology supportive care product in Canada. Gelclairwas our third new product launch in Canada in 2023, preceded by Inofolic in the third quarter, and FeraMAX Pd Maintenance 45 in the first quarter. Although we incurred incremental selling and marketing expenses associated with these three launch products during 2023, our net profit margin of 20% for the year was consistent with 2022. As we continued to execute and invest in our strategic priorities of profitable long-term growth and product portfolio diversification during 2023, we are also proud to have concurrently returned nearly $5 million in capital to our shareholders during the year through both regular quarterly dividends and ongoing share buybacks. I look forward to reporting on our continued progress towards our strategic priorities during 2024."
BioSyent總裁兼首席執行官雷內·戈赫魯姆評論說：“我們報告稱，在我們成熟產品的推動下，2023年第四季度加拿大藥品銷售額創歷史新高，比上期增長了10％。”在 2023 年第四季度，我們還開始分銷新款 Gelclair 加拿大的腫瘤學支持護理產品。蓋爾克萊爾是我們在 2023 年在加拿大推出的第三款新產品，之前是 Inofolic 在第三季度，還有 FeraMax 第一季度警局維護45％。儘管我們在2023年增加了與這三款上市產品相關的銷售和營銷費用，但該年度的淨利潤率爲20％，與2022年持平。隨着我們在2023年繼續執行和投資我們的戰略優先事項，即盈利的長期增長和產品組合多元化，我們也很自豪地通過定期季度分紅和持續的股票回購在年內同時向股東返還了近500萬美元的資本。我期待着報告我們在2024年期間在實現戰略優先事項方面的持續進展。”
The CEO's presentation on the Q4 and FY 2023 Results is available at the following link: .
首席執行官關於第四季度和2023財年業績的演示可通過以下鏈接獲得： 。
The Company's Audited Consolidated Financial Statements and Management's Discussion and Analysis for the years ended December 31, 2023 and 2022 will be posted on on March 13, 2024.
公司截至2023年12月31日和2022年12月31日止年度的經審計的合併財務報表以及管理層的討論和分析將發佈於 2024 年 3 月 13 日。
For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit .
如需多倫多證券交易所風險交易所的直接市場報價和其他公司財務信息，請訪問 。
About BioSyent Inc.
關於 BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.
BioSyent在多倫多證券交易所風險投資交易所上市，交易代碼爲 “RX”，是一家以增長爲導向的盈利型專業製藥公司，專注於許可或收購創新藥物和其他醫療保健產品，這些產品已成功開發，安全有效，在改善患者生活方面有着良好的記錄。BioSyent通過其社區、專業和國際業務部門銷售其產品，爲治療這些患者的醫療保健專業人員提供支持。
As of the date of this press release, the Company has 11,612,179 common shares outstanding.
截至本新聞稿發佈之日，該公司已發行11,612,179股普通股。
| BioSyent Inc. | ||||||||||||
| Consolidated Statements of Comprehensive Income | ||||||||||||
| In Canadian Dollars | Q4 2023 | Q4 2022 | % Change | FY 2023 | FY 2022 | % Change | ||||||
| Net Revenues | 8,273,686 | 7,461,930 | 11% | 31,590,302 | 27,925,187 | 13% | ||||||
| Cost of Goods Sold | 1,569,181 | 1,268,322 | 24% | 5,992,359 | 5,067,304 | 18% | ||||||
| Gross Profit | 6,704,505 | 6,193,608 | 8% | 25,597,943 | 22,857,883 | 12% | ||||||
| Operating Expenses and Finance Income/Costs | 4,849,767 | 4,541,558 | 7% | 17,064,090 | 15,427,232 | 11% | ||||||
| Net Income Before Tax | 1,854,738 | 1,652,050 | 12% | 8,533,853 | 7,430,651 | 15% | ||||||
| Tax (including Deferred Tax) | 403,947 | 452,534 | -11% | 2,073,726 | 1,972,306 | 5% | ||||||
| Net Income After Taxes | 1,450,791 | 1,199,516 | 21% | 6,460,127 | 5,458,345 | 18% | ||||||
| Net Income After Taxes % to Net Revenues | 18% | 16% | 20% | 20% | ||||||||
| EBITDA1 | 1,650,301 | 1,568,032 | 5% | 7,926,478 | 7,432,996 | 7% | ||||||
| EBITDA1 % to Net Revenues | 20% | 21% | 25% | 27% | ||||||||
| BioSyent Inc. | ||||||||||||
| 合併綜合收益表 | ||||||||||||
| 以加元計 | 2023 年第四季度 | 2022 年第四季度 | % 變化 | 2023 財年 | 2022 財年 | % 變化 | ||||||
| 淨收入 | 8,273,686 | 7,461,930 | 11% | 31,590,302 | 27,925,187 | 13% | ||||||
| 銷售商品的成本 | 1,569,181 | 1,268,322 | 24% | 5,992,359 | 5,067,304 | 18% | ||||||
| 毛利 | 6,704,505 | 6,193,608 | 8% | 25,597,943 | 22,857,883 | 12% | ||||||
| 運營費用和財務收入/成本 | 4,849,767 | 4,541,558 | 7% | 17,064,090 | 15,427,232 | 11% | ||||||
| 稅前淨收入 | 1,854,738 | 1,652,050 | 12% | 8,533,853 | 7,430,651 | 15% | ||||||
| 稅款（包括遞延稅） | 403,947 | 452,534 | -11% | 2,073,726 | 1,972,306 | 5% | ||||||
| 稅後淨收入 | 1,450,791 | 1,199,516 | 21% | 6,460,127 | 5,458,345 | 18% | ||||||
| 稅後淨收入佔淨收入的百分比 | 18% | 16% | 20% | 20% | ||||||||
| EBITDA1 | 1,650,301 | 1,568,032 | 5% | 7,926,478 | 7,432,996 | 7% | ||||||
| EBITDA1 佔淨收入的百分比 | 20% | 21% | 25% | 27% | ||||||||
1. EBITDA – is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.
1。息稅折舊攤銷前利潤 — 是非國際財務報告準則的財務指標。根據國際財務報告準則（IFRS），息稅折舊攤銷前利潤一詞沒有任何標準化含義，因此可能無法與其他公司提出的類似指標相提並論。公司將息稅折舊攤銷前利潤定義爲扣除利息收入或支出、所得稅、折舊和攤銷前的收益。
| BioSyent Inc. | ||||||
| Consolidated Statements of Financial Position | ||||||
| AS AT | December 31, 2023 | December 31, 2022 | % Change | |||
| ASSETS | ||||||
| Cash, cash equivalents and short-term investments | $ | 26,187,011 | $ | 28,695,644 | -9% | |
| Trade and other receivables | 3,477,096 | 3,498,355 | -1% | |||
| Inventory | 5,894,495 | 4,535,343 | 30% | |||
| Prepaid expenses and deposits | 243,460 | 254,958 | -5% | |||
| Loans receivable - current | 69,419 | 158,529 | -56% | |||
| CURRENT ASSETS | 35,871,481 | 37,142,829 | -3% | |||
| Long term investments | 2,500,000 | - | 100% | |||
| Loans receivable – non current | 205,182 | 258,240 | -21% | |||
| Deferred tax asset | 359,470 | 210,281 | 71% | |||
| Property and equipment | 1,439,930 | 1,673,036 | -14% | |||
| Intangible assets | 1,152,876 | 1,200,878 | -4% | |||
| TOTAL NON CURRENT ASSETS | 5,657,458 | 3,342,435 | 69% | |||
| TOTAL ASSETS | $ | 41,528,939 | $ | 40,485,264 | 3% | |
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||
| CURRENT LIABILITIES | $ | 5,533,850 | $ | 5,719,314 | -3% | |
| NON CURRENT LIABILITIES | 1,235,333 | 1,403,427 | -12% | |||
| Long term debt | - | - | 0% | |||
| Total Equity | 34,759,756 | 33,362,523 | 4% | |||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 41,528,939 | $ | 40,485,264 | 3% | |
| BioSyent Inc. | ||||||
| 合併財務狀況表 | ||||||
| 如 | 2023年12月31日 | 2022年12月31日 | % 變化 | |||
| 資產 | ||||||
| 現金、現金等價物和短期投資 | $ | 26,187,011 | $ | 28,695,644 | -9% | |
| 貿易和其他應收賬款 | 3,477,096 | 3,498,355 | -1% | |||
| 庫存 | 5,894,495 | 4,535,343 | 30% | |||
| 預付費用和按金 | 243,460 | 254,958 | -5% | |||
| 應收貸款-當前 | 69,419 | 158,529 | -56% | |||
| 流動資產 | 35,871,481 | 37,142,829 | -3% | |||
| 長期投資 | 2,500 | - | 100% | |||
| 應收貸款-非流動貸款 | 205,182 | 258,240 | -21% | |||
| 遞延所得稅資產 | 359,470 | 210,281 | 71% | |||
| 財產和設備 | 1,439,930 | 1,673,036 | -14% | |||
| 無形資產 | 1,152,876 | 1,200,878 | -4% | |||
| 非流動資產總額 | 5,657,458 | 3,342,435 | 69% | |||
| 總資產 | $ | 41,528,939 | $ | 40,485,264 | 3% | |
| 負債和股東權益 | ||||||
| 流動負債 | $ | 5,533,850 | $ | 5,719,314 | -3% | |
| 非流動負債 | 1,235,333 | 1,403,427 | -12% | |||
| 長期債務 | - | - | 0% | |||
| 權益總額 | 34,759,756 | 33,362,523 | 4% | |||
| 負債總額和股東權益 | $ | 41,528,939 | $ | 40,485,264 | 3% | |
For further information please contact:
欲了解更多信息，請聯繫：
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web:
René C. Goehrum 先生
總裁兼首席執行官
BioSyent 公司
電子郵件： investors@biosyent.com
電話：905-206-0013
網頁：
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
本新聞稿可能包含前瞻性的信息或陳述。此處的內容代表我們截至發佈之日的判斷，並且存在風險和不確定性，這些風險和不確定性可能會導致實際結果或結果與前瞻性信息或陳述存在重大差異。潛在風險可能包括但不限於與臨床試驗、產品開發、未來收入、運營、盈利能力和獲得監管部門批准相關的風險。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
多倫多證券交易所風險交易所及其監管服務提供商（該術語在多倫多證券交易所風險交易所的政策中定義）均不對本新聞稿的充分性或準確性承擔責任。